INS and type 1 diabetes mellitus: In the analysis considering only T1DM ICSRs, dapagliflozin was associated with an increased reporting frequency of ketoacidosis adverse events compared to insulin (ROR 9.60, 95%CI 8.13–11.32; Figure 2A), while no difference was observed compared to other SGLT2 inhibitors (ROR 1.11, 95%CI 0.92–1.35; Figure 2B).